This study is a new Phase II trial to assess the toxicity and efficacy of autologous
hematopoietic stem cell transplantation (HSCT) utilizing a new non-myeloablative conditioning
regimen in patients with high-risk Crohn's disease (CD). The regimen will include low-dose
immunosuppressive therapy and a targeted antibiotic for six to twelve months post-HSCT.